Filgia Dosage/Direction for Use

Dosage: Recommended Dose: 5 μg/kg body weight once daily. A CBC and platelet count should be obtained before instituting FILGIA therapy and monitored twice weekly during therapy. FILGIA should be administered daily for up to 2 weeks, until the ANC has reached 10,000/mm³ following the expected chemotherapy-induced neutrophil nadir. The duration of FILGIA therapy needed to attenuate chemotherapy-induced neutropenia may be dependent on the myelosuppressive potential of the chemotherapy regimen employed.
FILGIA therapy should be discontinued if the ANC surpasses 10,000/mm³ after the expected chemotherapy-induced neutrophil nadir.
Administration: FILGIA may be administered as SC bolus injection or as a short IV infusion, diluted in 5% glucose solution, given over 30 minutes. FILGIA should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. FILGIA should not be administered in the period 24 hours before the administration of chemotherapy.
In patients receiving cytotoxic chemotherapy, a transient increase in neutrophil counts is typically seen 1-2 days after initiation of FILGIA therapy. However, for a sustained therapeutic response, FILGIA therapy should not be discontinued before the expected nadir has passed and the neutrophil counts has recovered to the normal range. The required duration of treatment can be up to 14 days, depending on the type, dose and schedule of cytotoxic chemotherapy used.